Their onset of action is within 15 min after subcutaneous injection, and they have a faster and greater peak action. Insulin glargine, the first long-acting insulin analog to reach the market, was initially proclaimed to have the ideal “peakless,” nearly 24-h duration of action.15 However...
Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P 150 mg/dl) occurred later with glargine (22 +/- 4 h) than with NPH (14 +/- 3...
A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus To describe clinical outcomes in youth with new-onset type 1 diabetes mellitus (T1DM) treated with a modified, twice-daily regimen of a mixture of...
The potential benefits of rapid-acting insulin analogs versus regular human insulin are that the analogs have earlier onset and peak of biologic activity, resulting in lower postprandial glucose levels; a shorter duration of action, resulting in less late-prandial hypoglycemia; and less biologic variab...
The onset of the hypoglycaemic action in type IIa diabetics is significantly more rapid with isophane human insulin than with isophane pork insulin. The use of an insulin pump prior to testing the duration of action of intermediate insulin preparations appears to be superior to other methods.R....